Front. Public Health Frontiers in Public Health Front. Public Health 2296-2565 Frontiers Media S.A. 10.3389/fpubh.2022.862266 Public Health Systematic Review The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis Li Shudi 1 Liu Jiangkai 2 Wang Zhen 2 Duan Fei 2 Jia Zi 1 Chen Xinju 2 Li Suling 2 * 1Henan University of Chinese Medicine, Zhengzhou, China 2The First Affiliated Hospital of Henan University of TCM, Zhengzhou, China

Edited by: Foong Ming Moy, University of Malaya, Malaysia

Reviewed by: Doaa El Amrousy, Tanta University, Egypt; Antonella Mosca, Bambino Gesù Children's Hospital (IRCCS), Italy

 *Correspondence: Suling Li hk-lsl@163.com

This article was submitted to Public Health and Nutrition, a section of the journal Frontiers in Public Health

 25 07 2022 2022 10 862266 25 01 2022 01 07 2022 Copyright © 2022 Li, Liu, Wang, Duan, Jia, Chen and Li. 2022 Li, Liu, Wang, Duan, Jia, Chen and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Background

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with a high prevalence worldwide, seriously harming human health, and its pathogenesis remains unclear. In recent years, increasing evidence has indicated that intestinal microbiota plays an important role in the occurrence and development of NAFLD. The regulation method of probiotics/prebiotics/synbiotics can alter the intestinal microbiota and has been suggested as an option in the treatment of NAFLD.

 Methods

Five databases of PubMed, Embase, the Cochrane Library, clinicaltrails.gov, and China National Knowledge Infrastructure were searched initially, and then the eligible studies were screened. Finally, the data of included studieswere extracted, combined and analyzed

 Results

A total of 29 randomized controlled trials involving 2,110 patients were included in this study. The results showed that using probiotics/prebiotics/synbiotics in the intervention group could reduce the levels of glucose (SMD = −0.23, 95% CI [−0.45, −0.01], P = 0.04), HOMA-IR (SMD = −0.47, 95% CI [−0.63, −0.31], P < 0.00001) and insulin (SMD = −0.46, 95% CI [−0.76, −0.16], P = 0.002) in sugar metabolism; in terms of lipid metabolism, the levels of TC (SMD = −0.62, 95%CI [−0.87, −0.36], P < 0.00001), and LDL-C (SMD = −0.57, 95%CI [−0.85, −0.28], P < 0.00001) were decreased; and the level of ALB was decreased in protein metabolism (SMD = −0.34, 95%CI [−0.61, −0.06], P = 0.02).

 Conclusions

Based on the current evidence, probiotics/prebiotics/synbiotics may improve energy metabolism biomarkers in the NAFLD population, but these effects still need to be confirmed by further research.

 Systematic Review Registration

https://www.crd.york.ac.uk/PROSPERO/#aboutpage.

 NAFLD probiotics prebiotics synbiotics microbiota modulation energy metabolism biomarkers Postdoctoral Research Foundation of China10.13039/501100010031 Introduction

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by excessive accumulation of fat in liver cells (1). It includes a wide range of pathological liver diseases, from simple accumulation of liver fat to nonalcoholic steatohepatitis (NASH) with or without fibrosis, which can eventually progress to cirrhosis and liver cancer (2). The global prevalence of NAFLD has reached 25.2%, posing a serious threat to human health (3). The pathogenesis of NAFLD is still unclear, and the widely accepted concept of “multiple strikes” highlights the important role of various genetic and environmental factors in the multifactorial pathogenesis of NAFLD (4). Currently, no effective drugs for NAFLD have been approved (5).

The intestinal microbiota is a collective term for a large number of microorganisms existing in the human intestinal tract, whose metabolic activities can affect nutrient absorption and energy homeostasis (6). Recent studies have shown that intestinal microbiota plays a vital role in the development and progression of NAFLD, including regulating energy homeostasis by increasing carbohydrate fermentation to short-chain fatty acids, and activating the resynthesis of triglycerides and bacterial-derived toxins in the liver (7–10). The interaction between the liver and intestine (gut-liver axis) is not only involved in the pathogenesis of NAFLD, but also may be an important factor leading to the progression of NAFLD to NASH and related liver fibrosis (11, 12).

Probiotics, prebiotics, and synbiotics (PPS) have been proved to be therapeutic methods that can change the composition of the microbiota and restore microbial balance (13). Probiotics are living non-pathogenic microorganisms, prebiotics are defined as indigestible fiber compounds, and synbiotics are combinations of probiotics and prebiotics. They can cause specific changes in the composition and activity of the gastrointestinal microbiota when ingested, and increase the secretion of endogenous intestinal nutrient peptides (14). Studies have shown that PPS can regulate the composition of intestinal flora and the production of antibacterial factors, change the permeability and function of intestinal epithelial cells and reduce the permeability of intestinal endotoxin to affect the occurrence and development of NAFLD. They can also exert effects on NAFLD by modifying endotoxemia, inhibiting inflammatory response, and regulating the immune system (15–17).The PPS regulation method has been suggested as a treatment for NAFLD (18), and a number of randomized controlled trials have been conducted in clinical practice to confirm that PPS regulation can improve NAFLD. However, most studies have focused on the improvement of liver function and inflammatory indicators in NAFLD by the PPS regulation method, while there is a lack of systematic conclusions on the improvement effect of NAFLD on energy metabolism biomarkers. Based on this, this study adopts the method of meta-analysis to systematically evaluate PPS regulation on the energy metabolism biomarkers in NAFLD patients, in order to provide a reference and basis for the clinical practice of NAFLD.

 Materials and methods

The present study was conducted in accordance with the Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) statement to ensure transparent reporting of the scientific evidence (19), and was registered with PROSPERO in advance (CRD:42021288543, https://www.crd.york.ac.uk/PROSPERO/).

Inclusion and exclusion criteria

The included clinical studies met the following criteria: clinical trials were randomized controlled trials; participants were patients with NAFLD, regardless of age, gender, or race; the interventions were probiotics and/or prebiotics and/or synbiotics; except for the intervention method, the treatment of the control group was the same as that of the intervention group; the outcome measures included glucose (Glu), insulin, homeostatic model assessment of IR (HOMA-IR), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), albumin.

Exclusion criteria: patients with alcoholic steatohepatitis, alcoholic fatty liver, cirrhosis or liver cancer; patients receiving additional medication or genetic predisposition (single nucleotide polymorphisms); liver transplant patients; conference papers or abstracts; non-original research or case reports; and non-peer-reviewed articles.

 Database resources

We searched databases including PubMed, Embase, the Cochrane Library, clinicaltrails.gov, China National Knowledge Infrastructure.

 Search strategy

Related terms of “probiotics”, “prebiotics”, “synbiotics” and “nonalcoholic fatty liver disease” were used to search the above database. The search and selection period was from January 1, 2000 to September 31, 2021. The search strategies and results are detailed in the Appendix (see in Supplementary Table S1).

 Study selection protocol

The search and selection of studies were performed by three professionally trained researchers who were informed of inclusion and exclusion criteria prior to searching and selection. Studies were firstly screened by title and abstract, followed by further assessment of the full text based on inclusion and exclusion criteria. Finally, the screened full texts were compared. The three researchers negotiated and voted to resolve disagreements and discrepancies.

 Data synthesis and analysis

The statistical analysis was carried out using statistical software RevMan Version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) and the standard mean difference (SMD) synthesis was used uniformly since the outcome indicators included in this study were all continuous values. If the data were available and sufficient, we would also conduct subgroup analyses, based primarily on the type of diease (NAFLD/NASH), type of intervention (probiotic, prebiotic, synbiotic), type of control (placebo/non placebo), administratingduration ( ≤ 12 weeks; >12 weeks, <24 weeks; ≥24 weeks). I2 test was used to assess the magnitude of heterogeneity. The fixed-effects model was used only when the I2 value was <50%; otherwise, the random-effects model was used. The sensitivity analysis and subgroup analysis would be performed to define the source of heterogeneity. Any referenced statistic adopted a two-sided test, and the significance level was set as 0.05.

 Risk of bias and study quality assessment

Two authors independently evaluated the titles and abstracts of available articles to exclude irrelevant studies. Full texts of selected articles were assessed individually for eligibility on the basis of the above inclusion criteria. The Cochrane Collaboration's Risk of Bias tool was used to assess bias in the eligible RCTs. Sensitivity analysis was conducted by deleting the included studies in sequence to identify the stability of the total effect. If there were more than 10 articles for a certain outcome index, a funnel plotwas used to analyze whether publication bias existed. And Egger's test was conducted to qualify the publication bias, trim-and-fill method was applied to test how much influence the publicationbias would make on the pooling estimates.

 Results Study selection

According to the formulated strategy, 1,415 articles were preliminarily retrieved up to November 2, 2021, and 29 RCTs were finally included, as shown in Figure 1.

PRISMA flow diagram.

 Basic characteristics and assessment of study quality

Among the 29 included studies (20–48), 20 of them evaluated probiotics, 3 evaluated prebiotics, and 9 evaluated synbiotics, with a total of 2,110 patients enrolled. The characteristics of the included studies are shown in Table 1. Subgroup analysis was performed according to the preset grouping basis and no difference was found except for the subgroups of LDL-C disease. The risk of bias assessment was carried out employing the tool provided by the Cochrane Collaboration, and the results showed that the overall risk of the included studies was medium and low, as shown in Figure 2.

Characteristics of the included studies.

Reference Study type E/C m/f (E; C) Age (E/C) BMI (E/C) Disease Duration (weeks) Outcomes (effect size)
Abdel Monem (20) RCT 15/15 9/6 8/7 44.20 ± 5.51 44.33 ± 5.62 32.56 ± 1.19 33.05 ±1.27 NASH 4 ALB(−0.09[−0.80,0.03])
Detail of Intervention and Control: PRO(acidophilus, tid) +ALS vs. ALS
Ahn et al. (21) RCT-DB 30/35 15/17 18/18 41.7 ± 12.49 44.71 ± 13.31 30.05 ± 28.8 30.11 ± 29.1 NAFLD 12 TC(−0.11[−0.59,0.38]), TG(−0.39[−0.88,0.11]), HDL-C(−0.03[−0.52,0.46]), HOMA-IR(−0.80[−1.31,−0.29]), Insulin(−0.29[−0.78,0.20]), Glucose(−0.18[−0.67,0.31])
Detail of Intervention and Control: PRO(acidophilus CBTLA1, L. rhamnosus
CBT LR5, L.paracaseiCBT LPC5,P. pentosaceus CBTSL4,B. lactis CBTBL3,B.breve CBTBR3, qd) vs. Placebo
Alisi et al. (22) RCT-DB 22/22 10/12 14/8 NA 27.3/25.6 NAFLD 16 TG(0.18[−0.42,0.77])
Detail of Intervention and Control: PRO(VSL#3, 1-sachet, qd) vs. Placebo
Bakhshimoghaddam et al. (23) RCT 32/28 17/17 17/17 38.8 ± 9.0 41.1 ± 8.5 30.5 ± 4.6 31.3 ± 5.1 31.9 ± 5.1 NAFLD 24 HOMA-IR(−0.66[−1.18,−0.14]), Insulin(−0.61[−1.13,−0.09])
Detail of Intervention and Control: SYN(lactisBB+inulin,300g, qd)+ADL vs. ADL
Behrouz et al. (24) RCT-DB 30 29 30 22/8 20/9 21/9 38.46 ± 7.11 38.41 ± 9.21 38.42 ± 10.09 29.56 ± 2.54 30.81 ± 4.74 31.90 ± 5.04 NAFLD 12 Insulin: Pre vs. Placebo: −0.44[−0.96,0.77] Pro vs. Placebo: −0.48[−1.00,0.04] HOMA-IR: Pre vs. Placebo: −0.22[−0.73,0.29] Pro vs. Placebo: −0.27[−0.78,0.25] Glucose: Pre vs. Placebo: −0.03[−0.54,0.47] Pro vs. Placebo: −0.19[−0.70,0.32]
Detail of Intervention and Control: PRO(Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium breve, bid)/PRE(Orafti P95, bid) vs. Placebo
Bomhof et al. (25) RCT 8/6 5/3 3/3 45.3 ± 5.6 53.3 ± 4.8 33.7 ± 3.0 34.8 ± 2.2 NASH 36 Glucose: 0.20[−0.86,1.26] Insulin: −0.57[−1.66,0.51]
Detail of Intervention and Control: PRE(Orafti P95,8g,bid) vs. Placebo
Cai et al. (26) RCT 70/70 46/24 39/31 46.13 ± 12.72 49.62 ± 9.08 31.28 ± 3.62 30.73 ± 3.47 NAFLD 12 TC: −0.60[−0.94,−0.26] TG: −0.42[−0.75,−0.08] LDL-C: −0.30[−0.70,−0.03] HDL-C: 0.00[−0.33,0.33] HOMA-IR: −0.50[−0.83,−0.16]
Detail of Intervention and Control: PRO(Live Combined Bifidobacterium, Lactobacillus, Enterococcus Powder, 1g, bid)+ADL vs. ADL
Ekhlasi et al. (27) RCT-DB 15/15 NA NA 27.28 ± 2.21/ 27.84 ± 1.96 NAFLD 8 Glucose: −2.39[-3.36,−1.43] HOMA-IR: 0.06[-065,0.78] TG: −0.84[−1.59,−0.09] TC: −2.85[-3.90,−1.79] HDL-C: 0.27[−0.45,0.99] LDL-C: −2.61[-3.62,−1.61] Insulin: −2.25[-3.21,−1.31]
Detail of Intervention and Control: SYN(PRO(Lactobacillus casei, Lactobacillusrhamnosus, Streptococcusthermophilus, Bifidobacterium breve,
Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus)+PRE (fructooligosaccharide),2 capsule, qd) vs. placebo
Famouri et al. (28) RCT-DB 32/32 NA 12.7 ± 2.2 12.6 ± 1.7 26.4 ± 4.3 26.61 ± 2.26 NAFLD 12 TC: −0.23[−0.72,0.26] HDL-C: −0.14[−0.63,0.35] LDL-C: −0.25[−0.74,0.24] TG: −0.21[−0.70,−0.28]
Detail of Intervention and Control: PRO(Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, 1 capsule, qd) vs. Placebo
Javadi et al. (29) RCT-DB 20 19 17 19 17/3 16/3 14/3 13/6 43.90 ± 9.02 38.68 ± 10 43.24 ± 6.95 42.21 ± 9.11 29.91 ± 3.88 30.96 ± 4.39 32.30 ± 4.78 30.38 ± 2.88 NAFLD 12 ALB: Pre vs. Placebo: −0.64[−1.29,−0.01] Pro vs. Placebo: −0.67[−1.33,−0.02] Syn vs. Placebo: −0.52[−1.19,0.15])
Detail of Intervention and Control: PRO((Bifidobacterium longum, Lactobacillus acidophilus)/PRE(inulin HP)/SYN(PRO+PRE), 500mg, qd) vs. Placebo
Kobyliak et al. (30) RCT-DB 30/28 NA 53.4 ± 9.55 57.29 ± 10.45 34.82 ± 6.84 34.26 ± 6.17 NAFLD 8 TC: −0.01[−0.53,0.50] TG: 0.48[−0.04,1.00] HDL-C: 0.00[−0.52,0.52], LDL-C; −0.04[−0.56,0.47]
Detail of Intervention and Control: PRO(Lactobacillus, Lactococcus, Bifidobacteriu, Propionibacterium, Acetobacter,10g, qd) vs. Placebo
Malaguarnera et al. (31) RCT-DB 34/32 18/16 15/17 46.9 ± 5.4 46.7 ± 5.7 27.3 ± 1.36 27.2 ± 1.32 NAFLD 24 TC: −0.44[−0.92,0.05] HDL-C: 0.15[−0.34,0.63] LDL-C: −0.93[−1.43,−0.42] TG: −0.40[−0.89,0.09] HOMA-IR: −0.89[−1.40,−0.38] ALB: 0.00[−0.48,0.48] Insulin: −0.42[−0.91,0.06] Glucose: 0.04[−0.44,0.53]
Detail of Intervention and Control: SYN(Bifidobacterium longum +Fos, 10g, qd) vs. Placebo
Manzhalii et al. (32) RCT 38/37 11/27 16/21 43.5 ± 1.3 44.3 ± 1.5 26.4 ± 0.8 26.6 ± 0.7 NASH 12 TC: −4.45[-5.31,-3.59] TG: −0.20[−0.65,0.26] Glucose: −0.21[−0.66,0.25]
Detail of Intervention and Control: SYN(LBSF, qd) +ALS vs. ALS
Mofidi et al. (33) RCT-DB 21/21 11/10 12/9 40.09 ± 11.44 44.61 ± 10.12 23.17 ± 1.0123.20 ± 1.07 NAFLD 28 TC: −0.71[−1.33,−0.08] TG: −0.66[−1.28,−0.44] Glucose: −0.21[−0.66,0.25] LDL-C: −0.29[−0.90,0.32] HDL-C: 0.46[−0.15,1.07] HOMA-IR: 1.68[0.97,2.39] Insulin: 0.05[−0.65,0.56]
Detail of Intervention and Control: SYN (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus,
Bifidobacterium longum and Lactobacillus bulgaricus+Fos, 1s, bid) vs. Placebo
Mohamad Nor et al. (34) RCT-DB 17/22 11/6 17/5 54.70 ± 10.19 52.47 ± 16.73 31.33 ± 12.02 28.30 ± 3.90 NAFLD 24 TC: 0.17[−0.46,0.81] TG: −0.04[−0.67,0.59] Glucose: 0.67[0.02,1.32]
Detail of Intervention and Control: PRO(MCP® BCMC®,bid) vs. Placebo
Mohammad Sadrkabir et al. (35) RCT 33/28 NA 43.26 ± 11.42 43.72 ± 10.76 31.87 ± 5.4 30.83 ± 4.6 NAFLD 8 TC: −0.59[−1.10,−0.07] TG: 0.28[−0.23,0.78] Glucose: 0.06[−0.45,0.56] LDL-C: −0.24[−0.75,0.26] HDL-C: −0.28[−0.79,0.22]
Detail of Intervention and Control: PRO(GeriLact, 500mg, bid) vs. Placebo
Nabavi et al. (36) RCT-DB 36/36 17/19 18/18 42.75 ± 8.72 44.05 ± 8.14 30.1 ± 3.61 31.4 ± 3.6 NAFLD 8 TC: −0.75[−1.23,−0.27] TG: −0.41[−0.87,0.08] HDL-C: 0.13[−0.60,0.33] LDL-C: −0.63[−1.11,−0.16] Glucose: −0.32[−0.78,0.15]
Detail of Intervention and Control: PRO yogurt(B.lactis Bb12, L.acidophilus La5, 500g, qd) vs. Conventional yogurt
Sayari et al. (37) RCT 70/68 NA 42.48 ± 11.41 43.42 ± 11.65 29.72 ± 3.62 29.54 ± 3.71 NAFLD 16 TC: −0.56[−0.90,−0.22] TG: 0.20[−0.13,0.54] HDL-C: (0.24[−0.10,0.57] LDL-C: −0.95[−1.30,−0.60] Glucose: −0.60[−0.95,−0.26]
Detail of Intervention and Control: SYN(Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium
longum, Streptococcus thermophilus+FOS, 500mg, qd)+Sitagliptin vs. Placebo+Sitagliptin
Scorletti et al. (38) RCT-DB 45/44 NA 50.2 ± 12.4 51.6 ± 13.1 32.9 ± 5.5 33.2 ± 4.9 NAFLD 24 TC: 0.13[−0.28,0.55] TG: −0.21[−0.62,0.21] HDL-C: 0.03[−0.38,0.45] LDL-C: −23[−0.64,0.19] Insulin: 0.11[−0.31,0.52] Glucose: −0.04[−0.45,0.38]
Detail of Intervention and Control: SYN(Bifidobacterium animalis subsp. lactis BB-12+FOS, qd) vs. Placebo
Sepideh et al. (39) RCT-DB 21/21 13/8 15/6 42.10 ± 1.99 47.33 ± 2.53 30.34 ± 1.17 29.50 ± 0.84 NAFLD 8 Glucose(−0.46[−1.07,0.15]), HOMA-IR(−0.58[−1.20,0.04]), Insulin(−0.57[−1.18,0.05])
Detail of Intervention and Control: PRO(Lactobacillus Casei,Lactobacillus acidophilus,Lactobacillus rhamnosus,Lactobacillus bulgaricus,Bifidobacterium breve,Bifidobacterium
breve,Bifidobacterium longum,and Streptococcus, qd) vs. Placebo
Shavakhi et al. (40) RCT-DB 31/32 NA NA 28.6 ± 2.0 28.2 ± 2.5 NASH 24 Glucose: −0.20[−0.70,0.29] TG: −0.68[−1.19,−0.17] TC: −0.43[−0.93,0.07]
Detail of Intervention and Control: SYN(Lactobacillus acidophilus,Lactobacillus Casei,Lactobacillus rhamnosus,Lactobacillus bulgaricus,Bifidobacterium
breve,Bifidobacterium Longum,Streptococcus thermophilus+FOS, qd) +Metformin vs. Placebo+Metformin
Hu et al. (41) RCT 36/36 24/12 26/10 47.62 ± 16.41 49.56 ± 19.44 26.07 ± 3.7425.81 ± 3.52 NAFLD 12 TC: −0.50[−0.97,−0.03] TG: 3.80[3.01,4.59]
Detail of Intervention and Control: PRO(Bifidobacterium Lactobacillus, 2000mg, tid) +ALS vs. ALS
Ling et al. (42) RCT 35/35 17/18 20/15 41.6 ± 16.4 41.8 ± 15.3 NA NAFLD 16 TC: 0.02[−0.45,0.49] TG: −0.82[−1.31,−0.33] HDL-C: −0.15[−0.62,0.32] LDL-C: 0.20[−0.27,0.67] Glucose: 0.08[−0.39,0.55]
Detail of Intervention and Control: PRO(Bifidobacterium Lactobacillus, 420mg, Bid) +UDCA vs. UDCA
Wang et al. (43) RCT 60/60 NA NA NA NAFLD 12 TC: −0.27[−0.63,0.09] TG: 1.05[0.66,1.43] LDL-C: −0.05[−0.40,0.31] HDL-C: 0.27[−0.09,0.63] HOMA-IR: −0.28[−0.64,0.08]
Detail of Intervention and Control: PRO(Bifidobacterium Lactobacillus, 1000mg, qd) +ALS vs. ALS
Wei (44) RCT 51/51 33/18 31/20 47.64/46.83 NA NAFLD 12 TC: −0.60[−0.99,−0.20] TG: −0.66[−1.06,−0.27] HDL-C: 0.47[0.08,0.87] LDL-C; −0.82[−1.22,−0.41]
Detail of Intervention and Control: PRO(Bifidobacterium Lactobacillus, 1000mg, tid) +GSH vs. GSH
Wen et al. (45) RCT 40/40 27/13 25/15 39.58 ± 11.52 40.45 ± 10.93 NA NASH 24 TC: −1.03[−1.50,−0.56] TG: −3.68[-4.41,−2.95] HDL-C: −1.07[−1.54,−0.60] LDL-C: −1.58[−2.09,−1.08]
Detail of Intervention and Control: PRO(Bifidobacterium Lactobacillus, qd) +PPC vs. PPC
Zhang (46) RCT 60/60 52/8 50/10 75.3 ± 10.2 74.8 ± 11.3 23.56 ± 2.6823.74 ± 2.41 NAFLD 12 TC: −0.18[−0.54,0.18] TG: −0.29[−0.65,0.07]
Detail of Intervention and Control: PRO(Bifidobacterium,Lactobacillus,StreptococcusThermophilus, 4s, tid)+Conventional treatment vs. Conventional treatment
Zhao and Lv (47) RCT-DB 33/30 20/13 18/12 44.05 ± 11.06 43.14 ± 9.57 30.38 ± 3.14 29.54 ± 2.98 NAFLD 24 TC: −0.53[−1.04,−0.03] TG: −0.63[−1.14,−0.12]
Detail of Intervention and Control: PRO(Bifidobacterium Lactobacillus, 210mg, bid) vs. Placebo

Risk-of-bias graph.

 Effect on sugar metabolism

A meta-analysis was carried out on the three glucose metabolism indicators of Glucose, HOMA-IR, and Insulin. And we also conduct subgroup analyses, based primarily on the types of diease (NAFLD/NASH), types of intervention (probiotic, prebiotic, synbiotic), type of control (placebo/non placebo), administrating duration ( ≤ 12 weeks; >12 weeks, <24 weeks; ≥24 weeks), but no significant difference was found between subgroups (see in Supplementary Figures S1–S11).

Glucose

Glucose was reported in 15 studies involving 985 patients. The combined estimated value was SMD = −0.23 (95% CI [−0.45, −0.01], P = 0.04, I2 = 65%, random-effects model), and the difference was statistically significant, suggesting that the PPS regulation method could reduce glucose in NAFLD patients, as shown in Figure 3.

The role of PPS in Glucose in patients with NAFLD.

 HOMA-IR

HOMA-IR was reported in 9 studies involving 684 patients. The combined estimate was SMD = −0.29, (95% CI [−0.63, −0.06], P = 0.11, I2 = 79%, random-effects model). Sensitivity analysis showed that the study of Mofidi (32) affected the robustness of the pooled estimates, and after excluding this study, the results showed SMD = −0.47 (95% CI [−0.63, −0.31], P < 0.00001, I2 = 17 %, fixed-effects model), with a statistically significant difference. The heterogeneity of this study was analyzed, and it was considered that due to the normal range of BMI (23.17 ± 1.01/23.20 ± 1.07), the included population of the study were NAFLD patients with normal BMI and not accompanied by overweight, while the other studies concerning this indicator all included overweight NAFLD patients with BMI above the normal range. It was indicated that PPS regulation could reduce HOMA-IR in NAFLD patients, as shown in Figure 4.

The role of PPS in HOMA-IR in patients with NAFLD.

 Insulin

Insulin was reported in 9 studies involving 527 patients, with a combined estimate of SMD = −0.46 (95%CI [−0.76, −0.16], P = 0.002, I2 = 62%, random-effects model), and the differences were statistically significant, suggesting that PPS regulation could reduce insulin in NAFLD patients (Figure 5).

The role of PPS in Insulin in patients with NAFLD.

 Effect on lipid metabolism

A meta-analysis was carried out on the four lipid metabolism indicators of TC,TG,HDL-C,LDL-C. And we also conduct subgroup analyses, based primarily on the types of disease (NAFLD/NASH), types of intervention (probiotic, prebiotic, synbiotic), type of control (placebo/non placebo), administrating duration ( ≤ 12 weeks; >12 weeks, <24 weeks; ≥24 weeks). Only in the LDL-C, a statistically significant difference was found between subgroups according to disease types, and no significant difference was found in others (see in Supplementary Figures S12–S27).

TC

TC was reported in 22 studies involving 1,726 patients, with a combined estimated value of SMD = −0.62 (95% CI [−0.87, −0.36], P < 0.00001, I2 = 85%, random-effect model), indicating that PPS regulation could reduce TC in NAFLD patients, as shown in Figure 6.

The role of PPS in TC in patients with NAFLD.

 TG

A total of 23 studies involving 1,770 patients reported the indicator of TG, and the pooled estimate was SMD = −0.24 (95% CI [−0.59, −0.12], P = 0.19, I2 = 92%, random-effects model). The difference was not statistically significant, as shown in Figure 7.

The role of PPS in TG in patients with NAFLD.

 HDL-C

HDL-C was reported in 15 studies involving 1,197 patients, and the pooled estimate was SMD = 0.01, (95% CI [−0.18, 0.19], P = 0.95, I2 = 59%, random-effects model), with no statistically significant difference (see Figure 8).

The role of PPS in LDL-C in patients with NAFLD.

 LDL-C

LDL-C was reported in 14 studies involving 1,132 patients, and the combined estimate was SMD = −0.57 (95% CI [−0.85, −0.28], P < 0.00001, I2 = 81%), with a statistically significant difference. Subgroup analysis of the included studies revealed a statistically significant difference between the two groups according to disease type (P = 0.0001), but the reliability of inter-group differences was insufficient as only one study was included in the NASH group. Overall meta-analysis results suggested that PPS regulation could reduce LDL-C in NAFLD patients, as shown in Figure 9.

The role of PPS in HDL-C in patients with NAFLD.

 Effect on protein metabolism

A meta-analysis was carried out on the protein metabolism indicator of ALB. And we also conducted subgroup analyses, based primarily on the types of intervention (probiotic, prebiotic, synbiotic), type of control (placebo/non placebo), but no significant difference was found between subgroups (see in Supplementary Figures S28, S29).

ALB

The indicator of ALB was reported in five studies involving 209 patients. The combined estimated value was SMD = −0.34 (95%CI [−0.61, −0.06], P = 0.02, I2 = 11%, fixed-effects model), and the difference was statistically significant, suggesting that PPS regulation could reduce ALB in NAFLD patients (see Figure 10).

The role of PPS in ALB in patients with NAFLD.

 Sensitivity analysis and publication bias

Meta-analysis and sensitivity analysis was conducted on all preset indicators, and sensitivity analysis showed no changes in robustness except for the indicator of HOMA-IR. The funnel plots of glucose, HOMA-IR, TC, TG, LDL-C, and HDL-C were analyzed respectively, publication bias was qualified by Egger's test and found in HOMA-IR, TG, LDL-C and HDL-C, no significant differences were found after utilizing trim-and-fill method (see in Supplementary Figures S30–S35).

 Discussion

The current study systematically evaluated the effects of PPS regulation on energy metabolism biomarkers in NAFLD patients. The results showed that PPS regulation significantly improved the sugar and lipid metabolism indicators of NAFLD, and may have a negative impact on protein metabolism. Subgroup analysis, based on the types of disease (NAFLD/NASH), types of intervention(probiotic, prebiotic, synbiotic), type of control(placebo/non placebo), administrating duration( ≤ 12 weeks; >12 weeks, <24 weeks; ≥24 weeks), shows no statistically difference. No significant publication bias was identified.

According to the results of this study, the PPS regulation method may reduce the levels of glucose, HOMA-IR and insulin in NAFLD patients, and thus play a certain role in regulating the sugar metabolism level of patients. In 70–80% of NAFLD patients, there is a problem of elevated blood glucose (3), and studies by Mirmiranpour et al. have shown that PPS regulation can reduce blood glucose levels (49). PPS may improve the blood glucose problem in NAFLD by changing intestinal microflora and stimulating the production of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptides (GLPs), thereby increasing glucose uptake and lowering blood glucose levels (50). This study showed that PPS regulation reduced the glucose level in NAFLD (SMD = −0.23, 95%CI [−0.45, −0.01], P = 0.04), which is consistent with the above research. Insulin resistance is one of the characteristics of NAFLD (51), and HOMA-IR is the most widely used model method to evaluate insulin resistance in microbial therapy. The study by Nazarii et al. showed that PPS regulation can reduce the HOMA-IR level and improve insulin resistance (52). Previous studies have suggested that PPS may increase insulin sensitivity and improve NAFLD insulin resistance by regulating the NF-κB signaling pathway, reducing the expression of TNF-α and inflammatory response (53). Insulin resistance is associated with increased LPS levels, and impaired intestinal barrier leads to increased LPS levels in the circulation (54). PPS regulation may improve insulin resistance by regulating the production of tight junction protein mucin, improving the non-specific intestinal barrier defense mechanism, and reducing LPS levels (17, 55). The results of this study showed that PPS regulation could reduce the level of HOMA-IR (SMD = −0.47, 95%CI [−0.63, −0.31], P < 0.00001), suggesting that PPS regulation might improve insulin resistance in NAFLD. Elevated serum fasting insulin level is regarded as one of the main pathogenic factors of NAFLD (56), and PPS regulation is considered to reduce insulin levels (57). The exact mechanism by which the PPS regulation method affects insulin levels is unclear, and since PPS use glucose as the primary energy source, their effects on serum insulin levels may be mediated by affecting blood glucose levels (58). The results of this study showed that PPS regulation could reduce insulin levels (SMD = −0.46, 95% CI [−0.76, −0.16], P = 0.002), further providing evidence-based proof for this view.

This study showed that PPS regulation could reduce the levels of TC and LDL-C in NAFLD patients, while there was no significant difference in the indicators of TG and HDL-C. Elevated TC is an important risk factor for the pathogenesis of NAFLD (59), and low HDL-C and high LDL-C are characteristics of NAFLD (60, 61). Studies have shown that PPS regulation can reduce TC and LDL-C levels and increase HDL-C levels (62), and PPS may regulate cholesterol metabolism in NAFLD patients. The results of this study showed that PPS regulation could reduce the levels of TC (SMD = −0.62, 95%CI [−0.87, −0.36], P < 0.00001) and LDL-C (SMD = −0.57, 95%CI [−0.85, −0.28], P < 0.00001). Although there was no statistical difference in HDL-C, the overall effect size suggested that PPS regulation could increase the HDL-C level [SMD = 0.01, (95%CI [−0.18, 0.19], P = 0.95], providing support for the view that microbial therapy can regulate cholesterol metabolism. Elevated TG is also a risk factor for NAFLD (59), and studies have shown that PPS regulation can reduce the TG level (62). PPS may change the gene expression of lipogenic enzymes and reduce the de novo synthesis of fatty acids in the liver, thereby reducing the accumulation of triglycerides in the liver (63); TG levels are reduced by inhibiting the transcription of carbohydrate response element binding protein (ChREBP) and activating the transcription of peroxisome proliferator-activated receptor alpha (PPARα) encoding genes (64). Although the analysis results of this study showed no statistically significant difference in the effect of PPS regulation on the indicator of TG, the overall effect size suggested that the TG level decreased (SMD = −0.24, 95%CI [−0.59, −0.12], P = 0.19), indicating that PPS regulation may reduce the TG level in NAFLD.

This study also found that PPS regulation may reduce ALB levels (SMD = −0.34, 95% CI [−0.61, −0.06], P = 0.02). Intestinal microbiota can produce amino acids by fermenting dietary proteins, utilize amino acids for protein synthesis, and catabolize amino acids through deamination and decarboxylation (65–67). As an important protein in the human body, ALB plays an important role in maintaining body nutrition and osmotic pressure, and is the most important indicator reflecting liver synthesis function (68). A study showed that ALB level was negatively correlated with liver fibrosis indicators of LN and PC III in NAFLD patients (69). There are few previous studies on the effect of PPS regulation on protein metabolism. Considering the important role of intestinal microbiota in the process of protein synthesis and metabolism and the vital regulatory effect of microbial therapy on intestinal microbiota, PPS regulation may affect protein metabolism of NAFLD by regulating intestinal microbiota. However, this study only included five groups of comparisons on the indicator of ALB, three of which were from the same study. Due to limited data sources, the results should be interpreted with caution.

NASH is a progressive form of NAFLD. This study showed that PPS regulation could reduce the levels of Glucose, Insulin, TC, TG, HDL-C and LDL-C in NASH patients. Studies have shown that PPS regulation could prevent obesity and improve liver histology in NASH, which might be outcomes of regulating aforementioned indicators (16, 70). Moreover, in animal models, PPS could accelerate the lowering of plasma glucose levels during an insulin tolerance test in diet-induced obesity mice, and plays a certain role in regulating the sugar metabolism (71). Bile acid (BA) is essential for lipid and carbohydrate metabolism (72). PPS has been found possessing a certain effect on regulating BA synthesis to control lipid and sugar metabolism, and furthermore resisting the development of NASH (73). Despite aforementioned evidences, we have not found more evidences to explore the differences in the effects of PPS on NAFLD and NASH in terms of sugar, lipids, and proteins metabolism, future research might be needed.

On the basis of what we found, administration of PPS might be applied in more clinical scenario. Supplementation of PPS to regulate the gut microbiota should be explorably applied in the conventional treatment of NAFLD for PPS might has the potential to prevent the progression of NAFLD to NASH. PPS could reduce glucose, insulin and insulin resistance levels in NAFLD patients by restoring the homeostasis of gut microbiota, improved glucose metabolism disorders, and has application advantages in diseases including NAFLD and type 2 diabetes (T2D) which generally comorbid with abnormal glucose metabolism (26, 38). PPS could improve lipid metabolism disorder and reduced blood lipid and cholesterol levels in NAFLD patients. The potential mechanisms related to the hypocholesterolemic effect was that PPS could prevent free bile acids reabsorption and compensatory increased use of cholesterol to produce bile acids, which could lead to a reduction in the cholesterol present in serum (74). Evidence supports that PPS can improve cardiovascular disease risk factors, and it is suggested that it could be considered in the treatment of atherosclerosis and hypertension (75–77). This study showed that microbial therapy may reduce the ALB level of NAFLD patients, suggesting that we should pay attention to the impact of microbial therapy on protein metabolism and timely supplement protein when treating NAFLD.

The present study also has some limitations. (1) The sample size of the included studies was small with few relevant studies on certain indicators, and there were differences in the types, doses, intervention time of probiotics and lifestyle management in the included RCTs. In addition, a few of the trial designs were not standardized enough, which affected the effectiveness of the evaluation. (2) The included study involved adverse reactions of microbial therapy, and its side effects on NAFLD need to be further studied. (3) Although the risk of bias result for this study was medium and low, we couldn't be sure what impact of the risk would be. (4) Because the inconsistent bacteria strains and dose, a dose-response analysis was not applicable, more attention should be paid to this problem in further studies.

 Conclusions

The results of this study suggest that microbial therapy has a certain effect on the energy metabolism of NAFLD, and can be used as a new treatment option for NAFLD, but meanwhile, attention should be paid to its effect on protein reduction. However, the results of our study should be interpretated cautiously for the limitations in our study.

 Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

 Author contributions

Conceptualization: ShL and SuL. Methodology: ZW, FD, ZJ, and XC. Software: ShL, ZW, and JL. Validation, writing—review and editing, and supervision: ShL, SuL, JL, FD, ZJ, XC, and ZW. Writing—original draft preparation: ShL. Funding acquisition: SuL, XC, and FD. All authors have read, critically appraised, and agreed to the published version of the manuscript.

 Funding

This study was funded by the National Science and Technology major projects (Project Code: 2018ZX10303502); China Postdoctoral Science Foundation Special Funding for New Coronary Pneumonia Epidemic Prevention and Control (Project Code: 2020T130032ZX); Scientific research project of Henan Provincial Administration of Traditional Chinese Medicine (No. 20-21ZY1011; No. 2022ZY1002; No. 2018ZY2033).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.862266/full#supplementary-material

 References Eslam M Sarin SK Wong VW Fan JG Kawaguchi T Ahn SH . The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. (2020) 14:889–919. 10.1007/s12072-020-10094-233006093 Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastro Hepat. (2010) 7:195–203. 10.1038/nrgastro.2010.2120195271 Younossi ZM Golabi P de Avila L Paik J. M. Srishord M. Fukui N. . Global epidemiology of NAFLD and NASH in patients with type 2 diabetes:a systematic review and meta-analysis. J Hepatol. (2019) 71, 793–801. 10.1016/j.jhep.2019.06.02131279902 Cohen JC Horton JD Hobbs HH. Human fatty liver disease:old questions and new insights. Science. (2011) 332:1519–23. 10.1126/science.120426521700865 Golabi P Sayiner M Fazel Y Koenig A Henry L Younossi ZM . Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. (2016) 10:63. 10.1586/17474124.2016.109943326469309 Ley RE Peterson DA Gordon JI. Ecological and evolu-tionary forces shaping microbial diversity in the human intestine. Cell. (2006) 124:837–48. 10.1016/j.cell.2006.02.01716497592 Jumpertz R Le DS Turnbaugh PJ Trinidad C Bogardus C Gordon JI . Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. (2011) 94:58–65. 10.3945/ajcn.110.01013221543530 Hoverstad T Midtvedt T. Short-chain fatty acids in germfree mice and rats. J Nutr. (1986) 116:1772–6. 10.1093/jn/116.9.17723761032 Daly K Proudman CJ Duncan SH Flint HJ Dyer J Shirazi-Beechey SP . Alterations in microbiota and fermentation products in equine large intestine in response to dietary variation and intestinal disease. Br J Nutr. (2012) 107:989–95. 10.1017/S000711451100382521816118 Cani PD Amar J Iglesias MA Poggi M Knauf C Bastelica D . Metabolic endotoxemia initiates obesity and insulin resistance. Dia-betes. (2007) 56:1761–72. 10.2337/db06-149118042755 Park JS Seo JH Youn HS. Gut microbiota and clinical disease: obesity and nonalcoholic fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. (2013) 16:22–7. 10.5223/pghn.2013.16.1.2224010102 Seki E Schnabl B. Role of innate immunity and the microbiota in liver fibrossis: crosstalk between the liver and the gut. J Physiol. (2012) 590:447–58. 10.1113/jphysiol.2011.21969122124143 Malaguarnera M Greco F Barone G Gargante MP Malaguarnera M Toscano MA . Bifidobacterium longum with fructo-oligosac-charide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. (2007) 52:3259–65. 10.1007/s10620-006-9687-y17393330 Compare D Coccoli P Rocco A Nardone O De Maria M Cartenì S. Gut–liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. (2012) 22:471–6. 10.1016/j.numecd.2012.02.00722546554 Cani PD Possemiers S Van de Wiele T Guiot Y Everard A Rottier O . Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. (2009) 58:1091–103. 10.1136/gut.2008.16588619240062 Nardone G Rocco A. Probiotics: a potential target for the prevention and treatment of steatohepatitis. J Clin Gastroenterol. (2004) 38:121–2. 10.1097/01.mcg.0000128934.53920.1d15220676 Roberfroid M Gibson GR Hoyles L McCartney AL Rastall R Rowland I . Prebiotic effects:metabolic and health benefits. Br J Nutr. (2010) 104:1–63. 10.1017/S000711451000336334789345 Iacono A Raso GM Canani RB Calignano A Meli R . Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mecha-nisms. J Nutr Biochem. (2011) 22:699–711. 10.1016/j.jnutbio.2010.10.00221292470 Matthew JP Joanne EM Patrick MB Isabelle B Tammy CH Cynthia DM . The PRISMA. 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. (2021) 29:89. 10.1186/s13643-021-01626-433781348 Abdel Monem SM. Probiotic therapy in patients with nonalcoholic steatohepatitis in Zagazig University Hospitals. Euroasian J Hepatogastroenterol. (2017) 7:101–6. 10.5005/jp-journals-10018-122629201787 Ahn SB Jun DW Kang BK Lim JH Lim S Chung MJ . Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci Rep-uk. (2019) 9:5688. 10.1038/s41598-019-42059-330952918 Alisi A Bedogni G Baviera G Giorgio V Porro E Paris C . Randomised clinical trial: the beneficial effects ofVSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharm Ther. (2014) 39:1276–85. 10.1111/apt.1275824738701 Bakhshimoghaddam F Shateri K Sina M Hashemian M Alizadeh M. Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr. (2018) 148:1276–84. 10.1093/jn/nxy08829931231 Behrouz V Jazayeri S Aryaeian N Zahedi MJ Hosseini F. Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-alcoholic fatty liver disease: a randomized clinical trial. Middle East J Dig Dis. (2017) 9:151–9. 10.15171/mejdd.2017.6628894517 Bomhof MR Parnell JA Ramay HR Crotty P Rioux KP Probert CS . Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. (2019) 58:1735–45. 10.1007/s00394-018-1721-229779170 Cai GS Su H Zhang J. Protective effect of probiotics in patients with non-alcoholic fatty liver disease. Medicine. (2020) 99:21464. 10.1097/MD.000000000002146432769877 Ekhlasi G Mohammadi RK Agah S Zarrati M Hosseini AF Arabshahi SS . Do symbiotic and vitamin e supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci. (2016) 21:106. 10.4103/1735-1995.19317828250783 Famouri F Shariat Z Hashemipour M Keikha M Kelishadi R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J Pediatr Gastr Nutr. (2017) 64:413–7. 10.1097/MPG.000000000000142228230607 Javadi L Ghavami M Khoshbaten M Safaiyan A Barzegari A Gargari BP . The effect of probiotic and/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: a double blind randomized clinical trial. Iran Red Crescent Me. (2017) 19:46017. 10.5812/ircmj.46017 Kobyliak N Abenavoli L Mykhalchyshyn G Kononenko L Boccuto L Kyriienko D . Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: evidence from a Randomized Clinical Trial. J Gastrointest Liver. (2018) 27:41–9. 10.15403/jgld.2014.1121.271.kby29557414 Malaguarnera M Vacante M Antic T Giordano M Chisari G Acquaviva R . longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Digest Dis Sci. (2012) 57:545–53. 10.1007/s10620-011-1887-421901256 Manzhalii E Virchenko O Falalyeyeva T Beregova T Stremmel W. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial. J Digest Dis. (2017) 18:698–703. 10.1111/1751-2980.1256129148175 Mofidi F Poustchi H Yari Z Nourinayyer B Merat S Sharafkhah M . Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Brit J Nutr. (2017) 117:662–8. 10.1017/S000711451700020428345499 Mohamad Nor MH Ayob N Mokhtar NM Raja Ali RA Tan GC Wong Z . The effect of probiotics (MCP(®) BCMC(®) Strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease. Nutrients. (2021) 13:3192. 10.3390/nu1309319234579068 Mohammad Sadrkabir MD ShirinJahed MD Zahra Sadeghi MD KhaterehIsazadeh MD. The effect of gerilact on non-alcoholic fatty liver disease. J Kerman Univ Med Sci. (2020) 27:82–90. 10.22062/JKMU.2020.89598 Nabavi S Rafraf M Somi MH Homayouni-Rad A Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. (2014) 97:7386–93. 10.3168/jds.2014-850025306266 Sayari S Neishaboori H Jameshorani M. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. Clin Mol Hepatol. (2018) 24:331–8. 10.3350/cmh.2018.000629890569 Scorletti E Afolabi PR Miles EA Smith DE Almehmadi A Alshathry A . Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomizedtrial of patients with nonalcoholic fatty liver disease. Gastroenterology. (2020) 158:1597–610. 10.1053/j.gastro.2020.01.03131987796 Sepideh A Karim P Hossein A Leila R Hamdollah M Mohammad EG . Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. J Am Coll Nutr. (2016) 35:500–5. 10.1080/07315724.2015.103135526430826 Shavakhi A Minakari M Firouzian H Assali R Hekmatdoost A Ferns G . Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial. Int J Prev Med. (2013) 4:531–7.23930163 Hu X. Effect of probiotics in adjuvant treatment of non-alcoholic fatty liver dis-ease. Chin Modern Med. (2021) 28:167–70. 10.3969/j.issn.1674-4721.2021.25.04532436410 Ling L. Wang J. Dan G. (2019). Clinic efficacy of probiotics combined with ursodeoxycholic acid on non-alcoholic fatty liver disease. Lab Med Clin. 16:3413–5. 10.3969/j.issn.1672-9455.2019.23.006 Wang LJ Zhang JP Chen MH. Effects of probiotics on liver function, glucose and lipids metabolism, fecal flora in children with nonalcoholic fattyliver disease. Chin J School Health. (2019) 40:1545–8. 10.16835/j.cnki.1000-9817.2019.10.030 Wei XP. Effect of Probiotics combined with reduced glutathione on liver function and blood lipid level in patients with nonalcoholic fatty liver disease. Heilongjiang Med J. (2021) 45:722–4. 10.3969/j.issn.1004-5775.2021.07.017 Wen JF Ye GL Zhang HX Ding JX Chen SH. Clinical efficacy of bifidobacherium triple active bacteria combined with polyene phosphatidyl choline on NASH. Modern Chin Doc. (2014) 52:13–5. Zhang LN. Effects of Intestinal Probiotics on Liver and Kidney Metabolism in Nonalcoholic Fatty Liver Disease. Qingdao University, Qing Dao (2017). Zhao QW. LV DX. Probiotics for non-alcoholic fatty liver disease intervention effect. Chin J Mod Med. (2016) 54:29–33. Zheng D Wu J Gan HY Li H Ren HP Wang J . Clinical study of probiotics for non-alcoholic fatty liver disease. Chin J Clin Gastroenterol. (2018) 30:240–3. 10.3870/lcxh.j.issn.1005-541X.2018.04.09 Mirmiranpour H Huseini HF Derakhshanian H Khodaii Z Tavakoli-Far B. Effects of probiotic, cinnamon, and synbiotic supplementation on glycemic control and antioxidant status in people with type 2 diabetes, a randomized, double-blind, placebo-controlled study. J Diabetes Metab Disord. (2020) 61:1–19. 10.1007/s40200-019-00474-332550156 Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. (2007) 117:24–32. 10.1172/JCI3007617200703 Polyzos SA Kountouras J Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. (2009) 9:299–314. 10.2174/15665240978784719119355912 Nazarii K Tetyana F Galyna M Dmytro K Iuliia K. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial. Diabetes Metab Synd. (2018) 12:617–24. 10.1016/j.dsx.2018.04.01529661605 Esposito E Iacono A Bianco G Autore G Cuzzocrea S Vajro P . Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr. (2009) 139:905–11. 10.3945/jn.108.10180819321579 Luck H Tsai S Chung J Clemente-Casares X Ghazarian M Revelo XS . Regulation of obesity-related insulin resistance with gut anti -inflammatory agents. Cell Metab. (2015) 21:527–42. 10.1016/j.cmet.2015.03.00125863246 Wang X. Ota N. Manzanillo P. Kates L. Zavala-Solorio J. Eidenschenk C. . Interleukin- 22 alleviates met- abolic disorders and restores mucosal immunity in diabetes. Nature. (2014) 514:237–241. 10.1038/nature1356425119041 Pirgon O Bilgin H Cekmez F Kurku H Dündar BN. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr E. (2013) 5:33–9. 10.4274/Jcrpe.82523367495 Morvaridzadeh M Nachvak SM Mohammadi R Moradi S Mostafai R Pizarro AB . Probiotic yogurt fortified with vitamin D can improve glycemic status in non-alcoholic fatty liver disease patients: a randomized clinical trial. Clin Nutr Res. (2021) 10:36–47. 10.7762/cnr.2021.10.1.3633564651 Asemi Z Samimi M Tabassi Z Naghibi Rad M Rahimi Foroushani A Khorammian H . Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: a randomized controlled trial. Eur J Clin Nutr. (2013) 67:71–4. 10.1038/ejcn.2012.18923187955 Zheng RD Zhuang QY Chen JN Chen J Lu YH. Risk factors analysis of nonalcoholic fatty liver disease in Chinese men. Chin J hepatol. (2013) 21:62–5.23663766 Alberti KG Eckel RH Grundy SM Zimmet PZ Cleeman JI Donato KA . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity. Circulation. (2009) 120:1640–5. 10.1161/CIRCULATIONAHA.109.19264419805654 Liangpunsakul S Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci. (2005) 329:111–6. 10.1097/00000441-200503000-0000115767815 Wang C Zhang CC Li SJ Yu LL Tian FW Zhao JX . Effects of probiotic supplementation on dyslipidemia in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Foods. (2020) 9:1540. 10.3390/foods911154033114518 Delzenne NM Kok NN. Biochemical basis of oligofructose-induced hypolipide-mia in animal models. J Nutr. (1999) 129:1467–70. 10.1093/jn/129.7.1467S10395622 Wa Y Yin B He Y Xi W Huang Y Wang C . Effects of single probiotic- and combined probiotic- fermented milk on lipid metabolism in hyperlipidemic rats. Front Microbiol. (2019) 10:1312. 10.3389/fmicb.2019.0131231249562 Diether NE Willing BP. Microbial fermentation of diet-ary protein: An important factor in diet–microbe–host interaction. Microorganisms. (2019) 7:19. 10.3390/microorganisms701001930642098 Dai ZL Li XL Xi PB Zhang J Wu G Zhu WY . Metabolism of select amino acids in bacteria from the pig small intestine. Amino Acids. (2012) 42:1597–608. 10.1007/s00726-011-0846-x21344175 Fan P Li L Rezaei A Eslamfam S Che D Ma X . Metabolites of dietary protein and peptides by intestinal microbes and their impacts on gut. Curr Protein Pept Sc. (2015) 16:646–54. 10.2174/138920371666615063013365726122784 Friedman LS Martin P Munoz SJ. Laboratory evaluation of the patients with liver disease. In: Zakim D, Boyer TD, editors. Hepatology, 4th ed. (2003). Philadelphia: Saunder. p. 661–708. 10.11748/bjmy.issn.1006-1703.2020.08.020967362 Jiang L Yang GS Ma YC Ren SQ. The relationship between serum ALT, AST, ALB and liver fibrosis in patients with non-alcoholic fatty liver disease. Lab Immun Clin Med. (2020) 27:1363–6. Velayudham A Dolganiuc A Ellis M Petrasek J Kodys K Mandrekar P . VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. (2009) 49:989–97. 10.1002/hep.2271119115316 Naito E Yoshida Y Makino K Kounoshi Y Kunihiro S Takahashi R . Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol. (2011) 110:650–7. 10.1111/j.1365-2672.2010.04922.x21281408 Liu HX Keane R Sheng L Wan YJ. Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol. (2015) 63:1502–10. 10.1016/j.jhep.2015.08.00126256437 Jena PK Sheng L Nagar N Wu C Barile D Mills DA . Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models. J Nutr Biochem. (2018) 57:246–54. 10.1016/j.jnutbio.2018.04.00729800811 Reis S Conceição L Rosa D Siqueira N Peluzio M. Mechanisms responsible for the hypocholesterolaemic effect of regular consumption of probiotics. Nutr Res Rev. (2017) 30:36–49. 10.1017/S095442241600022627995830 Thushara RM Gangadaran S Solati Z Moghadasian MH. Cardiovascular benefits of probiotics: a review of experimental and clinical studies. Food Funct. (2016) 7:632–42. 10.1039/C5FO01190F26786971 Ahtesh FB Stojanovska L Apostolopoulos V. Anti-hypertensive peptides released from milk proteins by probiotics. Maturitas. (2018) 115:103–9. 10.1016/j.maturitas.2018.06.01630049341 Hassan A Din AU Zhu Y Zhang K Li T Wang Y . Updates in understanding the hypocholesterolemia effect of probiotics on atherosclerosis. Appl Microbiol Biotechnol. (2019) 103:5993–6006. 10.1007/s00253-019-09927-431201452